Establishment Labs (NASDAQ:ESTA) Stock Keeps Buy Rating at TD Cowen

Establishment Labs (NASDAQ:ESTA)‘s stock had its “buy” rating reissued by analysts at TD Cowen in a report released on Thursday, MarketBeat.com reports. They presently have a $117.00 target price on the stock. TD Cowen’s target price indicates a potential upside of 90.71% from the stock’s current price.

ESTA has been the subject of a number of other reports. Stifel Nicolaus set a $85.00 price objective on Establishment Labs and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, September 21st. Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a report on Thursday, August 13th. Needham & Company LLC increased their price objective on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Canaccord Genuity Group set a $105.00 price objective on Establishment Labs in a report on Thursday, August 6th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $98.56.

Establishment Labs Trading Up 6.0%

NASDAQ ESTA traded up $3.47 on Thursday, hitting $61.35. The company’s stock had a trading volume of 193,960 shares, compared to its average volume of 513,455. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. Establishment Labs has a 1-year low of $44.26 and a 1-year high of $97.59. The company’s 50-day moving average is $70.01 and its 200 day moving average is $74.43. The firm has a market cap of $1.83 billion, a PE ratio of -46.83 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The business had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The company’s revenue was up 31.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.57) earnings per share. As a group, analysts predict that Establishment Labs will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ESTA. KBC Group NV bought a new position in Establishment Labs during the first quarter worth $28,000. Integrated Wealth Concepts LLC bought a new position in shares of Establishment Labs in the second quarter valued at $32,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Establishment Labs in the second quarter valued at $43,000. State of Wyoming bought a new position in shares of Establishment Labs in the second quarter valued at $87,000. Finally, MV Capital Management Inc. bought a new position in shares of Establishment Labs in the fourth quarter valued at $146,000. 72.91% of the stock is owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc (NASDAQ: ESTA) is a medical technology company focused on women’s health and breast aesthetics. The company develops, manufactures and markets medical devices intended for breast augmentation, reconstruction and related procedures.

Its principal product portfolio includes Motiva breast implants, a line of silicone-gel implants designed for aesthetic and reconstructive applications, as well as tissue expanders and other products used in breast surgery. Establishment Labs also offers Mia Femtech, a technology and procedure platform designed to support a less invasive approach to breast augmentation.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves healthcare providers and patients in international markets.